Cargando…

Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)

BACKGROUND: To compare survival outcomes of patients with advanced or metastatic non‐small cell lung cancer (NSCLC) who received immunotherapy as first‐, second‐ or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. METHODS: A retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz‐Patiño, Alejandro, Arrieta, Oscar, Cardona, Andrés F., Martín, Claudio, Raez, Luis E., Zatarain‐Barrón, Zyanya L., Barrón, Feliciano, Ricaurte, Luisa, Bravo‐Garzón, María A., Mas, Luis, Corrales, Luis, Rojas, Leonardo, Lupinacci, Lorena, Perazzo, Florencia, Bas, Carlos, Carranza, Omar, Puparelli, Carmen, Rizzo, Manglio, Ruiz, Rossana, Rolfo, Christian, Archila, Pilar, Rodríguez, July, Sotelo, Carolina, Vargas, Carlos, Carranza, Hernán, Otero, Jorge, Pino, Luis E., Ortíz, Carlos, Laguado, Paola, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996989/
https://www.ncbi.nlm.nih.gov/pubmed/31828967
http://dx.doi.org/10.1111/1759-7714.13272
_version_ 1783493605568020480
author Ruiz‐Patiño, Alejandro
Arrieta, Oscar
Cardona, Andrés F.
Martín, Claudio
Raez, Luis E.
Zatarain‐Barrón, Zyanya L.
Barrón, Feliciano
Ricaurte, Luisa
Bravo‐Garzón, María A.
Mas, Luis
Corrales, Luis
Rojas, Leonardo
Lupinacci, Lorena
Perazzo, Florencia
Bas, Carlos
Carranza, Omar
Puparelli, Carmen
Rizzo, Manglio
Ruiz, Rossana
Rolfo, Christian
Archila, Pilar
Rodríguez, July
Sotelo, Carolina
Vargas, Carlos
Carranza, Hernán
Otero, Jorge
Pino, Luis E.
Ortíz, Carlos
Laguado, Paola
Rosell, Rafael
author_facet Ruiz‐Patiño, Alejandro
Arrieta, Oscar
Cardona, Andrés F.
Martín, Claudio
Raez, Luis E.
Zatarain‐Barrón, Zyanya L.
Barrón, Feliciano
Ricaurte, Luisa
Bravo‐Garzón, María A.
Mas, Luis
Corrales, Luis
Rojas, Leonardo
Lupinacci, Lorena
Perazzo, Florencia
Bas, Carlos
Carranza, Omar
Puparelli, Carmen
Rizzo, Manglio
Ruiz, Rossana
Rolfo, Christian
Archila, Pilar
Rodríguez, July
Sotelo, Carolina
Vargas, Carlos
Carranza, Hernán
Otero, Jorge
Pino, Luis E.
Ortíz, Carlos
Laguado, Paola
Rosell, Rafael
author_sort Ruiz‐Patiño, Alejandro
collection PubMed
description BACKGROUND: To compare survival outcomes of patients with advanced or metastatic non‐small cell lung cancer (NSCLC) who received immunotherapy as first‐, second‐ or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. METHODS: A retrospective cohort study of 296 patients with unresectable/metastatic NSCLC treated with either, first‐, second‐, third‐ or fourth‐line of immunotherapy was conducted. A matched comparison with a historical cohort of first‐line chemotherapy and a random forest tree analysis to characterize hyperprogressors was conducted. RESULTS: Median age was 64 years (range 34–90), 40.2% of patients were female. A total of 91.2% of patients had an Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1. Immunotherapy as first‐line was given to 39 patients (13.7%), second‐line to 140 (48.8%), and as third‐line and beyond to 108 (37.6%). Median overall survival was 12.7 months (95% CI 9.67–14 months) and progression‐free survival (PFS) of 4.27 months (95% CI 3.97–5.0). Factors associated with increased survival included treatment with immunotherapy as first‐line (P < 0.001), type of response (P < 0.001) and PD‐L1 status (P = 0.0039). Compared with the historical cohort, immunotherapy proved to be superior in terms of OS (P = 0.05) but not PFS (P = 0.2). A total of 44 hyperprogressors were documented (19.8%, [95% CI 14.5–25.1%]). Leukocyte count over 5.300 cells/dL was present in both hyperprogressors and long‐term responders. CONCLUSIONS: Patients who receive immune‐checkpoint inhibitors as part of their treatment for NSCLC have better overall survival (OS) compared with matched patients treated with standard chemotherapy, regardless of the line of treatment.
format Online
Article
Text
id pubmed-6996989
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-69969892020-02-05 Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP) Ruiz‐Patiño, Alejandro Arrieta, Oscar Cardona, Andrés F. Martín, Claudio Raez, Luis E. Zatarain‐Barrón, Zyanya L. Barrón, Feliciano Ricaurte, Luisa Bravo‐Garzón, María A. Mas, Luis Corrales, Luis Rojas, Leonardo Lupinacci, Lorena Perazzo, Florencia Bas, Carlos Carranza, Omar Puparelli, Carmen Rizzo, Manglio Ruiz, Rossana Rolfo, Christian Archila, Pilar Rodríguez, July Sotelo, Carolina Vargas, Carlos Carranza, Hernán Otero, Jorge Pino, Luis E. Ortíz, Carlos Laguado, Paola Rosell, Rafael Thorac Cancer Original Articles BACKGROUND: To compare survival outcomes of patients with advanced or metastatic non‐small cell lung cancer (NSCLC) who received immunotherapy as first‐, second‐ or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. METHODS: A retrospective cohort study of 296 patients with unresectable/metastatic NSCLC treated with either, first‐, second‐, third‐ or fourth‐line of immunotherapy was conducted. A matched comparison with a historical cohort of first‐line chemotherapy and a random forest tree analysis to characterize hyperprogressors was conducted. RESULTS: Median age was 64 years (range 34–90), 40.2% of patients were female. A total of 91.2% of patients had an Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1. Immunotherapy as first‐line was given to 39 patients (13.7%), second‐line to 140 (48.8%), and as third‐line and beyond to 108 (37.6%). Median overall survival was 12.7 months (95% CI 9.67–14 months) and progression‐free survival (PFS) of 4.27 months (95% CI 3.97–5.0). Factors associated with increased survival included treatment with immunotherapy as first‐line (P < 0.001), type of response (P < 0.001) and PD‐L1 status (P = 0.0039). Compared with the historical cohort, immunotherapy proved to be superior in terms of OS (P = 0.05) but not PFS (P = 0.2). A total of 44 hyperprogressors were documented (19.8%, [95% CI 14.5–25.1%]). Leukocyte count over 5.300 cells/dL was present in both hyperprogressors and long‐term responders. CONCLUSIONS: Patients who receive immune‐checkpoint inhibitors as part of their treatment for NSCLC have better overall survival (OS) compared with matched patients treated with standard chemotherapy, regardless of the line of treatment. John Wiley & Sons Australia, Ltd 2019-12-12 2020-02 /pmc/articles/PMC6996989/ /pubmed/31828967 http://dx.doi.org/10.1111/1759-7714.13272 Text en © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Ruiz‐Patiño, Alejandro
Arrieta, Oscar
Cardona, Andrés F.
Martín, Claudio
Raez, Luis E.
Zatarain‐Barrón, Zyanya L.
Barrón, Feliciano
Ricaurte, Luisa
Bravo‐Garzón, María A.
Mas, Luis
Corrales, Luis
Rojas, Leonardo
Lupinacci, Lorena
Perazzo, Florencia
Bas, Carlos
Carranza, Omar
Puparelli, Carmen
Rizzo, Manglio
Ruiz, Rossana
Rolfo, Christian
Archila, Pilar
Rodríguez, July
Sotelo, Carolina
Vargas, Carlos
Carranza, Hernán
Otero, Jorge
Pino, Luis E.
Ortíz, Carlos
Laguado, Paola
Rosell, Rafael
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
title Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
title_full Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
title_fullStr Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
title_full_unstemmed Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
title_short Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
title_sort immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (nsclc) compared with chemotherapy (quijote‐clicap)
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996989/
https://www.ncbi.nlm.nih.gov/pubmed/31828967
http://dx.doi.org/10.1111/1759-7714.13272
work_keys_str_mv AT ruizpatinoalejandro immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT arrietaoscar immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT cardonaandresf immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT martinclaudio immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT raezluise immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT zatarainbarronzyanyal immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT barronfeliciano immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT ricaurteluisa immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT bravogarzonmariaa immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT masluis immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT corralesluis immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT rojasleonardo immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT lupinaccilorena immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT perazzoflorencia immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT bascarlos immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT carranzaomar immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT puparellicarmen immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT rizzomanglio immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT ruizrossana immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT rolfochristian immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT archilapilar immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT rodriguezjuly immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT sotelocarolina immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT vargascarlos immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT carranzahernan immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT oterojorge immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT pinoluise immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT ortizcarlos immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT laguadopaola immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT rosellrafael immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap
AT immunotherapyatanylineoftreatmentimprovessurvivalinpatientswithadvancedmetastaticnonsmallcelllungcancernsclccomparedwithchemotherapyquijoteclicap